Compounding Certain Ibuprofen Oral Suspension Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act

[FDA]

This guidance describes the Food and Drug Administration’s (FDA or the Agency) regulatory and enforcement priorities regarding the compounding of certain ibuprofen oral suspension products in outsourcing facilities for administration in hospitals and health systems.


Baca selengkapnya di : http://www.fda.gov...